Your session is about to expire
← Back to Search
DWN12088 for Idiopathic Pulmonary Fibrosis
Study Summary
This trial tests a new drug, DWN12088, to see if it is safe and effective for treating Idiopathic Pulmonary Fibrosis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not pregnant or nursing.My health is stable enough for me to join a study, based on recent medical checks.I have been on a stable dose of IPF treatment for 3 months or have not taken any.Your lung function test result shows that the amount of oxygen your lungs can transfer to your blood is between 25% and 80% of what is expected.Your lung function is at least 40% of what is expected for someone your age and size.Your heart's electrical activity is not normal as shown by an ECG test.I have had a sudden worsening of my lung condition in the last 6 months.Your lung function, measured by the FEV1/FVC ratio, is normal before taking medication to widen the airways.I am 40 years old or older.I have been diagnosed with IPF according to specific lung association guidelines.
- Group 1: DWN12088 Xmg Tablet (BID)
- Group 2: Placebo 0mg Tablet (BID)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has DWN12088 been given the green light from the FDA?
"Due to the limited amount of evidence available for DWN12088's efficacy, it was given a safety ranking score of 2. However, there is some research that substantiates its safety."
What are the desired outcomes of this clinical experiment?
"The principal objective of this medical trial, which will be monitored over the course of 24 weeks, is to establish a rate for Forced Vital Capacity (FVC) decrease. Additionally, Quantitative High-Resolution Computed Tomography (HRCT), Time To Progression Of Idiopathic pulmonary fibrosis (IPF), and Diffusing Capacity Of Lung For Carbon Monoxide Corrected By Haemoglobin levels will also be tracked as secondary objectives."
Is this investigation accepting new recruits?
"Unfortunately, according to the details posted on clinicaltrials.gov, this particular medical trial is no longer recruiting participants; it was initially published on August 30th 2022 and last updated July 25th 2022. However, fortunately there are currently 410 other studies actively enrolling patients at this time."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger